{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:14:48Z","timestamp":1790162088188,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04343-3","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:14:42Z","timestamp":1777374882000},"page":"4728-4737","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world characterization of PD-L1 expression in patients with advanced esophagogastric adenocarcinoma in Spain"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4592-3813","authenticated-orcid":false,"given":"Paula","family":"Jimenez-Fonseca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Diez Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Luis","family":"Catoya-Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"P\u00e9rez-Wert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Visa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Carmona-Bayonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Luisa","family":"Lim\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Fern\u00e1ndez-Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Reboredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Vidal-Tocino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Gallego Plazas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo Eduardo","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Landolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Teijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Guerra-Pastrian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Dom\u00ednguez-Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Luisa","family":"L\u00f3pez-Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Rodr\u00edguez-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Jos\u00e9","family":"Ill\u00e1n-Gamb\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Mart\u00ednez de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinta","family":"Hierro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Gil-Raga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Robles Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Elena","family":"Moreno Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Vilanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Iglesias-Coma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"4343_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"4343_CR2","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1038\/s41388-020-1241-4","volume":"39","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Zhang J, Cheng ASL, Yu J, To KF, Kang W. Gastric cancer: genome damaged by bugs. Oncogene. 2020;39:3427\u201342.","journal-title":"Oncogene"},{"key":"4343_CR3","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.3389\/fonc.2020.01727","volume":"10","author":"J Yang","year":"2020","unstructured":"Yang J, Liu X, Cao S, Dong X, Rao S, Cai K. Understanding esophageal cancer: the challenges and opportunities for the next decade. Front Oncol. 2020;10:1727.","journal-title":"Front Oncol"},{"key":"4343_CR4","doi-asserted-by":"publisher","first-page":"104286","DOI":"10.18632\/oncotarget.22216","volume":"8","author":"WF Barra","year":"2017","unstructured":"Barra WF, Moreira FC, Pereira Cruz AM, Khayat AS, Calcagno DQ, Carneiro Dos Santos NP, et al. GEJ cancers: gastric or esophageal tumors? searching for the answer according to molecular identity. Oncotarget. 2017;8:104286\u201394.","journal-title":"Oncotarget"},{"key":"4343_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nature20805","volume":"541","author":"Integrated genomic characterization of oesophageal carcinoma","year":"2017","unstructured":"Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541:169\u201375.","journal-title":"Nature"},{"key":"4343_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182692","volume":"12","author":"L Gu","year":"2017","unstructured":"Gu L, Chen M, Guo D, Zhu H, Zhang W, Pan J, et al. PD-L1 and gastric cancer prognosis: a systematic review and meta-analysis. PLoS ONE. 2017;12:e0182692.","journal-title":"PLoS ONE"},{"key":"4343_CR7","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1158\/1078-0432.CCR-20-2980","volume":"27","author":"ZA Wainberg","year":"2021","unstructured":"Wainberg ZA, Fuchs CS, Tabernero J, Shitara K, Muro K, Van Cutsem E, et al. Efficacy of pembrolizumab monotherapy for advanced gastric\/gastroesophageal junction cancer with programmed death ligand 1 combined positive score \u226510. Clin Cancer Res. 2021;27:1923\u201331.","journal-title":"Clin Cancer Res"},{"key":"4343_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13000-023-01318-8","volume":"18","author":"C Liu","year":"2023","unstructured":"Liu C, Fang F, Kong Y, ElGabry EA. Tumor area positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring. Diagn Pathol. 2023;18:48.","journal-title":"Diagn Pathol"},{"key":"4343_CR9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10120-019-00999-9","volume":"23","author":"K Yamashita","year":"2020","unstructured":"Yamashita K, Iwatsuki M, Harada K, Eto K, Hiyoshi Y, Ishimoto T, et al. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer. Gastric Cancer. 2020;23:95\u2013104.","journal-title":"Gastric Cancer"},{"key":"4343_CR10","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1001\/jamaoncol.2022.3707","volume":"8","author":"HH Yoon","year":"2022","unstructured":"Yoon HH, Jin Z, Kour O, Kankeu Fonkoua LA, Shitara K, Gibson MK, et al. Association of PD-L1 expression and other variables with benefit from immune checkpoint inhibition in advanced gastroesophageal cancer: systematic review and meta-analysis of 17 phase 3 randomized clinical trials. JAMA Oncol. 2022;8:1456\u201365.","journal-title":"JAMA Oncol"},{"key":"4343_CR11","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398:759\u201371.","journal-title":"Lancet"},{"key":"4343_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340.","journal-title":"Lancet"},{"key":"4343_CR13","doi-asserted-by":"crossref","unstructured":"Janjigian Y, Moehler M, Ajani J, Shen L, Garrido M, Gallardo C, et al. Nivolumab (NIVO) chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer\/gastroesophageal junction cancer\/esophageal adenocarcinoma (GC\/GEJC\/EAC) 5-year (y) follow-up results from CheckMate. J Clin Oncol. 2025; 649:43","DOI":"10.1200\/JCO.2025.43.4_suppl.398"},{"key":"4343_CR14","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P, Bai Y, Ryu MH, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1181\u201395.","journal-title":"Lancet Oncol"},{"key":"4343_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078876","volume":"385","author":"MZ Qiu","year":"2024","unstructured":"Qiu MZ, Oh DY, Kato K, Arkenau T, Tabernero J, Correa MC, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ. 2024;385:e078876.","journal-title":"BMJ"},{"key":"4343_CR16","doi-asserted-by":"publisher","first-page":"330","DOI":"10.5858\/arpa.2018-0043-OA","volume":"143","author":"K Kulangara","year":"2019","unstructured":"Kulangara K, Zhang N, Corigliano E, Guerrero L, Waldroup S, Jaiswal D, et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med. 2019;143:330\u20137.","journal-title":"Arch Pathol Lab Med"},{"key":"4343_CR17","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/15384047.2022.2038002","volume":"23","author":"T Yoshida","year":"2022","unstructured":"Yoshida T, Ogura G, Tanabe M, Hayashi T, Ohbayashi C, Azuma M, et al. Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan. Cancer Biol Ther. 2022;23:191\u2013200.","journal-title":"Cancer Biol Ther"},{"key":"4343_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.783695","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen X, Zhang H, Wang M, Liu H, Hu Y, Lin T, et al. Relationship between programmed death ligand 1 expression and other clinicopathological features in a large cohort of gastric cancer patients. Front Immunol. 2022;13:783695.","journal-title":"Front Immunol"},{"key":"4343_CR19","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3390\/curroncol30020145","volume":"30","author":"R Mehta","year":"2023","unstructured":"Mehta R, Liepa AM, Zheng S, Chatterjee A. Real-world molecular biomarker testing patterns and results for advanced gastroesophageal cancers in the United States. Curr Oncol. 2023;30:1869\u201381.","journal-title":"Curr Oncol"},{"key":"4343_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-34434-y","volume":"13","author":"T Chitapanarux","year":"2023","unstructured":"Chitapanarux T, Gumrai P, Kongkarnka S, Wannasai K, Lertprasertsuke N. Programmed Death-Ligand 1 expression and overall survival in Thai patients with gastric cancer. Sci Rep. 2023;13:7241.","journal-title":"Sci Rep"},{"key":"4343_CR21","doi-asserted-by":"publisher","first-page":"18633","DOI":"10.1002\/cam4.6472","volume":"12","author":"M Shin","year":"2023","unstructured":"Shin M, Ahn S, Jung J, Hyung S, Kim KM, Kim ST, et al. Impact of programmed death-ligand 1 (PD-L1) positivity on clinical and molecular features of patients with metastatic gastric cancer. Cancer Med. 2023;12:18633\u201342.","journal-title":"Cancer Med"},{"key":"4343_CR22","unstructured":"Kakehi S, You M, Zhang Y, Smith M, Ray S. Real-world treatment and testing patterns for advanced\/metastatic gastric cancer\/gastroesophageal junction cancer\/esophageal"},{"key":"4343_CR23","first-page":"17","volume":"40","author":"Adenocarcinoma in the United States","year":"2024","unstructured":"Adenocarcinoma in the United States. Results from the Flatiron Health database. J Manag Care Spec Pharm. 2024;40:17.","journal-title":"J Manag Care Spec Pharm"},{"key":"4343_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11072003","author":"XJ Chen","year":"2023","unstructured":"Chen XJ, Wei CZ, Lin J, Zhang RP, Chen GM, Li YF, et al. Prognostic significance of PD-L1 expression in gastric cancer patients with peritoneal metastasis. Biomedicines. 2023. https:\/\/doi.org\/10.3390\/biomedicines11072003.","journal-title":"Biomedicines"},{"key":"4343_CR25","unstructured":"Spanish Registry of Esophagogastric Cancer (AGAMENON). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04958720."},{"key":"4343_CR26","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461\u201371.","journal-title":"Lancet"},{"key":"4343_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","volume":"392","author":"K Shitara","year":"2018","unstructured":"Shitara K, \u00d6zg\u00fcro\u011flu M, Bang YJ, Di Bartolomeo M, Mandal\u00e0 M, Ryu MH, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392:123\u201333.","journal-title":"Lancet"},{"key":"4343_CR28","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1200\/JCO.20.01888","volume":"38","author":"T Kojima","year":"2020","unstructured":"Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu CH, et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020;38:4138\u201348.","journal-title":"J Clin Oncol"},{"key":"4343_CR29","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.1158\/1078-0432.CCR-20-2790","volume":"27","author":"M Lei","year":"2021","unstructured":"Lei M, Siemers NO, Pandya D, Chang H, Sanchez T, Harbison C, et al. Analyses of PD-L1 and inflammatory gene expression association with efficacy of nivolumab \u00b1 ipilimumab in gastric cancer\/gastroesophageal junction cancer. Clin Cancer Res. 2021;27:3926\u201335.","journal-title":"Clin Cancer Res"},{"key":"4343_CR30","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1038\/s41379-021-00823-9","volume":"34","author":"S Ahn","year":"2021","unstructured":"Ahn S, Kim KM. PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28\u20138 pharmDx assays for responses to immunotherapy. Mod Pathol. 2021;34:1719\u201327.","journal-title":"Mod Pathol"},{"key":"4343_CR31","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s10120-022-01301-0","volume":"25","author":"J Yeong","year":"2022","unstructured":"Yeong J, Lum HYJ, Teo CB, Tan BKJ, Chan YH, Tay RYK, et al. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. Gastric Cancer. 2022;25:741\u201350.","journal-title":"Gastric Cancer"},{"key":"4343_CR32","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.21037\/jgo-21-505","volume":"12","author":"Y Narita","year":"2021","unstructured":"Narita Y, Sasaki E, Masuishi T, Taniguchi H, Kadowaki S, Ito S, et al. PD-L1 immunohistochemistry comparison of 22C3 and 28\u20138 assays for gastric cancer. J Gastrointest Oncol. 2021;12:2696\u2013705.","journal-title":"J Gastrointest Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04343-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04343-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04343-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:41:57Z","timestamp":1790160117000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04343-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["4343"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04343-3","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PJ-F declares consultant, advisory, or speaker roles from BMS. JLC-V has received research support\/funding\/grants from Advanz Pharma, and Escuela Andaluza de Salud P\u00fablica; speaker honorarium from AstraZeneca, Nutricia, PharmaMar, and Servier; travel support from Amgen, AstraZeneca, BMS, Esteve, Gilead, Ipsen, Jazz Pharmaceuticals, Lilly, Merck, MSD, Novartis, Nutricia, Pfizer, Pierre Fabre, Roche, Sanofi, Servier, Takeda. He also owns stocks in PharmaMar. AC-B has have received research support\/funding\/grants from Astra-Zeneca; speaker honorarium from Novartis and Astellas; consultant honorarium from Astellas; and travel support from Amgen, Astellas, and Servier. MLL has have received speaker honorarium from Bristol Myers Squibb, consultant honorarium from Astra Zeneca, and travel support from LEO FARMIS. AF-M has received speaker honorarium from Amgen, Merck, Sanofi, Servier, Astra Zeneca, Daichi-Sainchi, Takeda, MSD, BMS, BeOne, Asofarma, and Leo Pharma. She also has received consultant honorarium from Astra Zeneca, BeOne, BMS, Amgen, LeoPharma, and travel support from Roche, Takeda, and Astra Zeneca. RV-T declares consultant, advisory, or speaker roles for Amgen, Servier, BMS, Merck, MSD, Pierre-Fabre, Astellas, Bayer, GSK, and educational, scientific activities and travel and accommodation support from Roche, Servier, MSD, Merck, BMS and Amgen. JGP declares advisory role for Astellas, Beigene, BMS and MSD and speaker role for BMS. AT has received speaker honorarium from Be one, MSD and Astrazeneca. LG-P has received speaker honorarium from BMS. EMdC has received speaker honorarium from BMS, Astra Zeneca, MSD, Rovi, LeoPharma, Sanofi Aventis, Roche, Servier; consultant honorarium from BMS, Incyte, MSD, Servier; and travel support from Roche, Servier. CH declares consultancy roles (speaker and advisory roles) for Lilly, AstraZeneca, Bristol-Myers Squibb (BMS), MSD and Astellas. She has received research grants and support via Institution from Merck. She is involved as principal investigator in clinical trials from BMS, MSD, Jazz Pharmaceuticals, ALX Oncology, AstraZeneca, Relay Therapeutics, Abbie and Medicenna, and has received travel and accommodation expenses from Amgen, Roche, BMS, MSD, Jazz Therapeutics and Merck. MG-R has received speaker honorarium from Bristol, Servier, Astellas, Astrazeneca, and Merck; consultant honorarium from Bristol; travel support from Bristol, MSD, MErck, Amgen, and Servier; and has participated in advisory boards from Bristol. MI-C declares consultant, advisory, or speaker roles for Roche, Astellas, BMS, MSD, BeiGene, Gilead, AstraZeneca, Servier, Merck and Daichii-Sankyo. MRG, MEMG, and DV are employees at Bristol Myers Squibb. MDG, PP-W, LV, MR, GEM, SL, AN, JLD-M, MLL-V, MR-G, and FJI-G declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted following the Declaration of Helsinki and approved by the Ethical Committees of the participating hospitals (Approval number: 2023\/10865\/I from the first hospital, i.e. the Hospital del Mar Research Institute, Barcelona, Spain).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Except for deceased patients (in whom informed consent was waived), all patients provided a written informed consent to participate in the study.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}